For example, dual BRAF/MEK inhibition initially suppressed the mTOR complex I signaling pathway in melanoma cells in culture and patient-derived tumor xenografts in mice (PDX), but the pathway activity rebounded upon the acquisition of drug resistance in an AKT-dependent manner in PTEN-deficient melanoma cells [46]. This evidence concerns the gene PTEN and melanoma.